ABSTRACT
En la práctica dermatológica, se realizan diversos procedimientos quirúrgicos y estéticos que pueden causar dolor a los pacientes. Actualmente en el mercado se dispone, de un amplio arsenal de drogas que permiten lograr una anestesia segura y eficaz. Existen diferentes modalidades y técnicas de anestesia, según el tipo de intervención y el segmento corporal en el cual se va a realizar el procedimiento. Los efectos adversos de los diferentes anestésicos están bien definidos y se deben tomar ciertas precauciones en poblaciones especiales donde el riesgo de complicaciones es mayor. Es de fundamental importancia que el clínico posea un acabado conocimiento de los diversos fármacos utilizados en anestesia, para poder minimizar las complicaciones derivadas de su administración.
In dermatological practice, various surgical and cos-metic procedures are performed that can cause pain to patients. A large stock of drugs is now available on the market to provide safe and effective anesthesia. There are different modalities and techniques of anesthesia, depending on the type of intervention and the body segment in which the procedure will be performed. The adverse effects of different anesthe-tics are well defined and certain precautions should be taken in special populations where the risk of complications is greater. It is fundamental that the clinician has a thorough knowledge of the various drugs that can be used in anesthesia, in order to minimize complications arising from its administration
Subject(s)
Humans , Dermatology/instrumentation , Anesthesia/methods , Anesthetics/classification , Anesthetics, Local/administration & dosage , Anesthetics, Local/classification , Nerve Block/methodsABSTRACT
BACKGROUND: Acute Kidney Injury (AKI) increases morbidity, mortality and hospital stay in critical patients units (CPU). AIM: To determine the incidence and mortality of AKI in CPU. MATERIAL AND METHODS: Review of electronic medical records of 1,769 patients aged 61 ± 20 years (47% males) discharged from a CPU during one year. Acute Kidney Injury diagnosis and severity was established using the Acute Kidney Injury Network (AKIN) criteria. RESULTS: A history of hypertension and Diabetes Mellitus was present in 44 and 22% of patients, respectively. APACHE II and SOFA scores were 14.6 ± 6.8 and 3.6 ± 2.1 respectively. AKI incidence was 28.9% (stage I, 16.7%, stage II, 5.3% and stage III, 6.9%). Mortality during the first 30 days and during the first year was 8.1 and 20.0% respectively. Patients with stage III AKI had the highest mortality (23.8 and 40.2% at 30 days and one year respectively). Compared with patients without AKI, the Odds ratio for mortality at 30 days and one year of patients with AKI stage III was 3.7 and 2.5, respectively. CONCLUSIONS: Thirty percent of patients admitted to UPC develop an AKI, which influences 30 days and one year mortality.
Subject(s)
Acute Kidney Injury/mortality , Intensive Care Units/statistics & numerical data , Tertiary Care Centers/statistics & numerical data , Acute Kidney Injury/epidemiology , Adult , Aged , Aged, 80 and over , Diabetes Mellitus/mortality , Female , Hospital Mortality , Hospitalization/statistics & numerical data , Humans , Hypertension/mortality , Incidence , Male , Middle Aged , Prognosis , Retrospective Studies , Risk AssessmentABSTRACT
Background: Acute Kidney Injury (AKI) increases morbidity, mortality and hospital stay in critical patients units (CPU). Aim: To determine the incidence and mortality of AKI in CPU. Material and Methods: Review of electronic medical records of 1,769 patients aged 61 ± 20 years (47% males) discharged from a CPU during one year. Acute Kidney Injury diagnosis and severity was established using the Acute Kidney Injury Network (AKIN) criteria. Results: A history of hypertension and Diabetes Mellitus was present in 44 and 22% of patients, respectively. APACHE II and SOFA scores were 14.6 ± 6.8 and 3.6 ± 2.1 respectively. AKI incidence was 28.9% (stage I, 16.7%, stage II, 5.3% and stage III, 6.9%). Mortality during the first 30 days and during the first year was 8.1 and 20.0% respectively. Patients with stage III AKI had the highest mortality (23.8 and 40.2% at 30 days and one year respectively). Compared with patients without AKI, the Odds ratio for mortality at 30 days and one year of patients with AKI stage III was 3.7 and 2.5, respectively. Conclusions: Thirty percent of patients admitted to UPC develop an AKI, which influences 30 days and one year mortality.